LIBFF

Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company

Novamind

TORONTO, ON / ACCESSWIRE / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, announces that it has made a strategic investment of US$1,000,000 (the "Strategic Investment") in a stealth mode drug development company based in the United States (... Read More...

377 views2 min read

Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board

Novamind

VANCOUVER, BC, Jan. 4, 2021 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing precli... Read More...

142 views2 min read

Nova Mentis Expands Psychedelic Drug Pipeline

Novamind

VANCOUVER, BC, Dec. 29, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeru... Read More...

25 views2 min read

Canada and Ontario invest in green infrastructure to support residents of Pays Plat First Nation and Biigtigong Nishnaabeg First Nation

Novamind

VANCOUVER, BC, Dec. 3, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiar... Read More...

M & A1210 views4 min read

Nova Mentis Life Science Completes Acquisition of Pilz Bioscience

Novamind

VANCOUVER, BC, Nov. 30, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news releases dated November 2 and November 18, 2020, the amalgamation between Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Compa... Read More...

M & A138 views4 min read

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update

Novamind

VANCOUVER, BC, Nov. 11, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has provided a corporate update.Dr. Marvin S. Hausman MD, Chairman and Chief Scientific Officer of Pilz commented: "We are very pleased wi... Read More...

M & A71 views4 min read

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement

Novamind

VANCOUVER, BC, Nov. 5, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have comp... Read More...

M & A832 views4 min read

Nova Mentis Life Science Signs Amalgamation Agreement to Acquire 100% of Pilz BioScience Corp.

Novamind

VANCOUVER, BC, Nov. 2, 2020 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA") is pleased to announce that, further to its news release dated October 9, 2020, it has entered into a definitive amalgamation agreement, (the "Definitive Agreement") with Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova ... Read More...

LIBFF

Make smarter investment strategies with in-depth news reports

Make smarter investment strategies
with in-depth news reports